text_1: 90% of patients with melanoma and an objective response to PD-1 blockade will experience a progression in their melanoma.
text_2: DESIGN, SETTINGS, AND PARTICIPANTS Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013).